Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKesson
Boehringer Ingelheim
Mallinckrodt
McKinsey

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Aleglitazar


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Aleglitazar?

Aleglitazar is an investigational drug.

There have been 22 clinical trials for Aleglitazar. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2010.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Cardiovascular Diseases. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].

Recent Clinical Trials for Aleglitazar
TitleSponsorPhase
A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)Hoffmann-La RochePhase 3
A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic TherapyHoffmann-La RochePhase 3
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin MonotherapyHoffmann-La RochePhase 3

See all Aleglitazar clinical trials

Clinical Trial Summary for Aleglitazar

Top disease conditions for Aleglitazar
Top clinical trial sponsors for Aleglitazar

See all Aleglitazar clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKesson
Boehringer Ingelheim
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.